NurExone Biologic (FRA:J90) Pretax Margin %: % (As of Mar. 2026)

What is NurExone Biologic Pretax Margin %?

NurExone Biologic FRA:J90 -0.60% 34 Pretax Margin % is % as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, NurExone Biologic ranks worse than 106157.01% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. NurExone Biologic's Pre-Tax Income for the three months ended in Mar. 2026 was €-1.53 Mil. NurExone Biologic's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, NurExone Biologic's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for NurExone Biologic's Pretax Margin % or its related term are showing as below:

FRA:J90's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

NurExone Biologic (FRA:J90) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

NurExone Biologic Pretax Margin % Related Terms

NurExone Biologic Pretax Margin % Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Pretax Margin % Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Dec25

Pretax Margin %

0.00

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Pretax Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:J90 vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, NurExone Biologic's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Pretax Margin % falls into.

Save Embed

34GF Score

NurExone Biologic Inc FRA:J90

Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NurExone Biologic Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

NurExone Biologic's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-5.452	/	0
	=	%

NurExone Biologic's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-1.528	/	0
	=	%

Frequently Asked Questions Learn more about Pretax Margin % →

What does a Pretax Margin % of % mean?

NurExone Biologic (FRA:J90) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NurExone Biologic and its competitors. According to the industry distribution chart, NurExone Biologic ranks #999999 out of 942 companies in the Biotechnology industry.

Is NurExone Biologic's Pretax Margin % too high?

NurExone Biologic's current Pretax Margin % is %. Based on the distribution chart, NurExone Biologic ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NurExone Biologic has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does NurExone Biologic's Pretax Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, NurExone Biologic ranks #999999 out of 942 companies for Pretax Margin %. This places NurExone Biologic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Pretax Margin % for a Biotechnology company?

A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Pretax Margin % mean?

A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NurExone Biologic stock overvalued right now?

NurExone Biologic (FRA:J90) has a current Pretax Margin % of %. The current Pretax Margin % is %. NurExone Biologic's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Pretax Margin % calculated?

Pretax Margin % is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Industry Healthcare Biotechnology

Comparable Companies TSX:SVA TSXV:MIR NEOE:ONCO XCNQ:METX XCNQ:TELI TSX:MBX TSXV:ARCH XCNQ:DTC TSX:BCT TSXV:EBM VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges NRXBF:USA NRX:Canada

Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.

34GF Score

Get the complete analysis for FRA:J90

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33

Price

View FRA:J90 Analysis

See Pretax Margin % data for all stocks →